A carregar...
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...
Na minha lista:
| Publicado no: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6827249/ https://ncbi.nlm.nih.gov/pubmed/31684985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1412-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|